Clinical features and prognosis in 104 colorectal cancer patients with bone metastases.
- Author:
Ruo-xi HONG
1
;
Qiu-ju LIN
;
Jian LUO
2
;
Zhen DAI
;
Wen-na WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bone Density Conservation Agents; therapeutic use; Bone Neoplasms; drug therapy; radiotherapy; secondary; Colorectal Neoplasms; drug therapy; pathology; radiotherapy; surgery; Diphosphonates; therapeutic use; Female; Follow-Up Studies; Fractures, Bone; etiology; Humans; Lumbar Vertebrae; pathology; Male; Middle Aged; Pain; etiology; Pelvic Bones; pathology; Prognosis; Retrospective Studies; Ribs; pathology; Sacrum; pathology; Spinal Cord Compression; etiology; Spinal Neoplasms; drug therapy; radiotherapy; secondary; Thoracic Vertebrae; pathology; Young Adult
- From: Chinese Journal of Oncology 2013;35(10):787-791
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical features and prognosis of bone metastases in colorectal cancer patients.
METHODSThe clinical data of 104 cases of colorectal cancer with bone metastasis were collected and retrospectively analyzed.
RESULTSAmong all the 104 patients included, 45 (43.3%) patients had multiple bone metastases, and 59 (56.7%) patients had single bone metastasis. Pelvis (46.1%) was the most common site, followed by thoracic vertebrae (41.3%), lumbar vertebrae (40.4%), sacral vertebrae (29.8%) and ribs (29.8%). One hundred and two patients (98.1%) were complicated with other organ metastases. The median time from colorectal cancer diagnosis to bone metastasis was 16 months, and the median time from bone metastasis to first skeletal-related events (SREs) was 1 month. The most common skeletal-related events (SREs) were the need for radiotherapy (44.2%), severe bone pain (15.4%) and pathologic fracture (9.6%). The median survival time of patients with bone metastases was 10.0 months, and 8.5 months for patients with SREs. ECOG score, systemic chemotherapy and bisphosphonate therapy were prognostic factors by univariate analysis (all P < 0.05). ECOG score and systemic chemotherapy were independent prognostic factors by Cox multivariate analysis.
CONCLUSIONSBone metastasis in colorectal cancer patients has a poor prognosis and the use of chemotherapy and bisphosphonates may have a benefit for their survival.
